ArticleKidney medicine2025
Identifying Barriers and Facilitators to Pain Management With Buprenorphine for Patients With Kidney Failure: A Thematic Analysis of Interviews With Key Partners.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Rationale & Objective: Treating pain with analgesic medications in patients with kidney failure receiving dialysis is often complicated owing to altered pharmacokinetics, affecting efficacy and safety of medications. Buprenorphine, a partial opioid agonist without these limitations, has potential value in pain treatment in kidney failure. The aim of this qualitative study was to identify barriers and facilitators to overcoming stigma for implementation of buprenorphine as a pain treatment in patients treated with dialysis. Study Design: Thematic analysis of interview data. Setting & Participants: We used snowball sampling to enroll physicians with expertise in pain management and kidney failure, and other key partners. Exposures: Participants completed semistructured interviews. Topics covered included facilitators and barriers to pain management and buprenorphine prescription for patients with kidney failure. Outcomes: Qualitative themes. Analytical Approach: Interviews were transcribed and coded using the MAXQDA software (VERBI Software). We performed a thematic analysis to determine the most salient themes. Results: Of the 26 participants, 17 were physicians with expertise in nephrology, addiction psychiatry, palliative care, internal medicine, and physical medicine and rehabilitation. The other 9 participants included representatives from payors, retail pharmacy, and dialysis organizations. We identified the following 5 themes: (1) lack of knowledge about buprenorphine, (2) pervasiveness of pain- and buprenorphine-related stigma, (3) perception of pain management as beyond nephrologists' scope of practice, (4) sociostructural barriers to pain management, and (5) suggestions to overcome the barriers. Limitations: Our sample had limited racial and ethnic diversity and may not represent the perspectives of key partners working within different health systems or geographic locations. Conclusions: Significant barriers to effective pain management and access to buprenorphine exist for patients with kidney failure at multiple levels (ie, patient, provider, organization, and systems levels). Therefore, multilevel interventions that include components that target patient stigma, clinician education, and increase collaboration among key partners are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.